Skip to main content

CORRECTION article

Front. Neurosci., 08 January 2024
Sec. Sleep and Circadian Rhythms
Volume 17 - 2023 | https://doi.org/10.3389/fnins.2023.1344915

Corrigendum: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

This article is a correction to:

  1. Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

    1. Read original article
\r\nSandra P. Smieszek Sandra P. Smieszek1*Alyssa R. KadenAlyssa R. Kaden1Caroline E. JohnsonCaroline E. Johnson1Jennifer L. BrzezynskiJennifer L. Brzezynski1Changfu XiaoChangfu Xiao1Christos M. PolymeropoulosChristos M. Polymeropoulos1Gunther BirznieksGunther Birznieks1Helene A. Emsellem,Helene A. Emsellem2,3Mihael H. PolymeropoulosMihael H. Polymeropoulos1
  • 1Vanda Pharmaceuticals Inc., Washington, DC, United States
  • 2The Center for Sleep & Wake Disorders, Chevy Chase, MD, United States
  • 3Department of Neurology, George Washington University, Washington, DC, United States

A corrigendum on
Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

by Smieszek, S. P., Kaden, A. R., Johnson, C. E., Brzezynski, J. L., Xiao, C., Polymeropoulos, C.M., Birznieks, G., Emsellem, H. A., and Polymeropoulos, M. H. (2023). Front. Neurosci. 17:1287514. doi: 10.3389/fnins.2023.1287514

In the published article, there was an error. (There was an omission).

A correction has been made to Discussion, Paragraph 4. This sentence previously stated:

“This participant is not a carrier of the variable number of tandem repeat (VNTR) PER34/4 genotype, associated with delayed sleep patterns, nor the CRY1 splicing variant (Patke et al., 2017). No other predicted loss-of-function mutations within circadian genes were identified.”

The corrected sentence appears below:

“This participant is not a carrier of the variable number of tandem repeat (VNTR) PER34/4 genotype, associated with delayed sleep patterns, nor the CRY1 splicing variant (Patke et al., 2017). This patient has been determined to carry two 5′ UTR region variants in the Atonal BHLH Transcription Factor 7 (ATOH7) gene known to be associated with ONH, rs61854782 and rs7916697. ATOH7 is expressed in retinal progenitor cells and has a crucial role in retinal ganglion cell development. No other predicted loss-of-function mutations within circadian genes were identified.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Patke, A., Murphy, P., Onat, O., Krieger, A., Özçelik, T., Campbell, S., et al. (2017). Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. Cell 169, 203–215.e1. doi: 10.1016/j.cell.2017.03.027

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: biological rhythms, circadian rhythm disorders, clinical trials research, sleep/wake mechanisms, Delayed Sleep-Wake Phase Disorder, delayed sleep, night owl, Optic Nerve Hypoplasia

Citation: Smieszek SP, Kaden AR, Johnson CE, Brzezynski JL, Xiao C, Polymeropoulos CM, Birznieks G, Emsellem HA and Polymeropoulos MH (2024) Corrigendum: Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study. Front. Neurosci. 17:1344915. doi: 10.3389/fnins.2023.1344915

Received: 27 November 2023; Accepted: 18 December 2023;
Published: 08 January 2024.

Edited and reviewed by: Melissa A. St. Hilaire, Merrimack College, United States

Copyright © 2024 Smieszek, Kaden, Johnson, Brzezynski, Xiao, Polymeropoulos, Birznieks, Emsellem and Polymeropoulos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sandra P. Smieszek, sandra.smieszek@vandapharma.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.